Wellcome Trust held its stake in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The hedge fund owned 1,750,000 shares of the company’s stock at the end of the fourth quarter. Johnson & Johnson accounts for 3.6% of Wellcome Trust’s portfolio, making the stock its 14th largest position. Wellcome Trust owned 0.06% of Johnson & Johnson worth $179,760,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Lowe FS boosted its position in Johnson & Johnson by 15.2% in the third quarter. Lowe FS now owns 379 shares of the company’s stock valued at $35,000 after buying an additional 50 shares during the last quarter. Creative Planning acquired a new position in Johnson & Johnson during the fourth quarter valued at $0. Lenox Wealth Advisors raised its position in Johnson & Johnson by 5.9% in the fourth quarter. Lenox Wealth Advisors now owns 1,065 shares of the company’s stock valued at $109,000 after buying an additional 59 shares during the period. Peavine Capital Management raised its position in Johnson & Johnson by 0.3% in the fourth quarter. Peavine Capital Management now owns 2,480 shares of the company’s stock valued at $255,000 after buying an additional 7 shares during the period. Finally, Berson & Corrado Investment Advisors acquired a new position in Johnson & Johnson during the fourth quarter valued at $261,000.

Johnson & Johnson (NYSE:JNJ) opened at 96.75 on Monday. Johnson & Johnson has a 12 month low of $81.79 and a 12 month high of $105.49. The company’s 50-day moving average is $100.95 and its 200 day moving average is $98.60. The company has a market cap of $267.70 billion and a price-to-earnings ratio of 18.57.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 8th. Shareholders of record on Tuesday, February 23rd will be issued a dividend of $0.75 per share. The ex-dividend date is Friday, February 19th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.61. This represents a $3.00 annualized dividend and a yield of 3.10%.

Several equities analysts have recently weighed in on JNJ shares. S&P Equity Research restated a “buy” rating and set a $120.00 price objective on shares of Johnson & Johnson in a research report on Thursday, October 15th. BTIG Research restated a “buy” rating and set a $115.00 price objective on shares of Johnson & Johnson in a research report on Sunday, November 1st. Deutsche Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $110.00 price objective for the company in a research report on Tuesday, September 29th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $105.00 price objective for the company in a research report on Thursday, October 1st. Finally, Vetr lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating and set a $103.34 price objective for the company. in a research report on Tuesday, September 29th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the stock. Johnson & Johnson has an average rating of “Hold” and an average price target of $106.92.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

12 Month Chart for NYSE:JNJ

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.